Skip to content
FY'25FY'24FY'23FY'22
Profitability
Gross margin84.5%+15.9pp68.6%-20.7pp89.3%-8.5pp97.8%+5.0pp
Net margin78.2%+525pp-446.9%-279pp-167.7%
Returns
Return on equity85.7%+294pp-207.8%-141pp-67.2%
Return on invested capital-49.9%+141pp-191.1%+85.5pp-276.6%
Efficiency
Asset turnover0.5×+0.3×0.1×-0.1×0.2×+0.1×0.1×-0.3×
Liquidity
Current ratio5.7×+3.2×2.5×+1.3×1.2×-6.5×7.7×-19.5×
Leverage
Debt-to-equity0.4×-1.1×1.5×+1.4×0.1×+0.1×0.0×
Per Share
Book value per share$2.70+215%$0.86
Valuation
Market capitalization$773.23M+56.4%$445.16M+79.3%$248.24M+56.7%$158.4M-48.6%
Price / earnings6.2×
Price / sales6.3×-5.9×18.9×+9.8×-6.5×15.6×+4.8×
Price / book3.8×-8.3×11.2×+7.2×+1.9×2.1×-0.9×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Zevra Therapeutics, Inc.'s profit margins?
Zevra Therapeutics, Inc. (ZVRA) runs a 86.1% gross margin and a -103.9% operating margin, with a 101.6% net margin.
Where do Zevra Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Zevra Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.